|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C28H22ClF3N6O3 |
|||
| Molecular Weight | 582.96 | CAS No. | 1448347-49-6 | |
| Solubility (25°C)* | In vitro | DMSO | 100 mg/mL (171.53 mM) | |
| Ethanol | 100 mg/mL (171.53 mM) | |||
| Water | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | Ivosidenib (AG-120) is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. | |
|---|---|---|
| Targets |
|
|
| In vitro | TF-1 cells or primary human AML patient samples expressing mutant IDH1 are treated with AG-120.Treatment with AG-120 decreases intracellular 2-HG levels, inhibites growth factor independent proliferation and restores erythropoietin (EPO)-induced differentiation in TF-1 IDH1-R132H cells. Similarly, pharmacological inhibition of mutant IDH1 enzyme with AG-120 in primary human blast cells cultured ex vivo provides an effective way to lower intracellular 2-HG levels and induces myeloid differentiation[1]. |
Protocol (from reference)
| Cell Assay: |
|
|---|
Customer Product Validation
-
Data from [Data independently produced by , , Oncol Rep, 2017, 38(6):3583-3591]
-
Data from [Data independently produced by , , ONCOLOGY REPORTS, 2017, 38: 3583-3591]
Selleck's Ivosidenib (AG-120) has been cited by 14 publications
| A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma [ EBioMedicine, 2024, 102:105090] | PubMed: 38547578 |
| Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability [ Cancer Discov, 2023, 13(2):496-515] | PubMed: 36355448 |
| ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia [ Nat Commun, 2023, 14(1):5709] | PubMed: 37726279 |
| ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia [ Nat Commun, 2023, 14(1):5709] | PubMed: 37726279 |
| Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation [ Cell Rep, 2023, 42(6):112578] | PubMed: 37267108 |
| Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia [ Nat Commun, 2022, 13(1):2614] | PubMed: 35551192 |
| Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma [ NPJ Precis Oncol, 2022, 6-1:61] | PubMed: 36056177 |
| Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity [ Front Pharmacol, 2022, 13:871392] | PubMed: 35418865 |
| The long non-coding RNA CDK6-AS1 overexpression impacts on acute myeloid leukemia differentiation and mitochondrial dynamics [ iScience, 2021, 24(11):103350] | PubMed: 34816103 |
| Exosomal IDH1 increases the resistance of colorectal cancer cells to 5-Fluorouracil [ J Cancer, 2021, 12(16):4862-4872] | PubMed: 34234856 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.